AR097790A1 - NASAL USE VACCINES AGAINST STREPTOCOCCUS PYOGENES BASED ON A WASTE BACTERIAL VECTOR AND SPECIFIC ANTIGENS, PRODUCTION METHOD - Google Patents

NASAL USE VACCINES AGAINST STREPTOCOCCUS PYOGENES BASED ON A WASTE BACTERIAL VECTOR AND SPECIFIC ANTIGENS, PRODUCTION METHOD

Info

Publication number
AR097790A1
AR097790A1 ARP140103580A ARP140103580A AR097790A1 AR 097790 A1 AR097790 A1 AR 097790A1 AR P140103580 A ARP140103580 A AR P140103580A AR P140103580 A ARP140103580 A AR P140103580A AR 097790 A1 AR097790 A1 AR 097790A1
Authority
AR
Argentina
Prior art keywords
protein
immunogenic formulation
clause
formulation according
strains
Prior art date
Application number
ARP140103580A
Other languages
Spanish (es)
Original Assignee
Pontificia Univ Católica De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Univ Católica De Chile filed Critical Pontificia Univ Católica De Chile
Publication of AR097790A1 publication Critical patent/AR097790A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Una formulación inmunogénica para inducir la respuesta inmune en un sujeto, que comprende una mezcla de cepas de bacterias no patógenas genéticamente modificadas que expresan cada una un segmento hipervariable de la proteína M de Streptococcus pyogenes diferente y un diluyente biológicamente aceptable. Uso de la formulación inmunogénica para preparar una vacuna de administración intranasal y un método para producir dicha vacuna. Reivindicación 3: Una formulación inmunogénica de acuerdo a la cláusula 1, caracterizada porque las bacterias no patógenas corresponden a bacterias de ácido láctico. Reivindicación 4: Una formulación inmunogénica de acuerdo a la cláusula 3, caracterizada porque las bacterias de ácido láctico utilizadas son de la especie Lactococcus Iactis. Reivindicación 6: Una formulación inmunogénica de acuerdo a la cláusula 1, caracterizada porque los segmentos hipervariables de la proteína M de S. pyogenes son expresados en un constructo. Reivindicación 9: Una formulación inmunogénica de acuerdo a la cláusula 8, caracterizada porque el plasmidio utilizado es el pNZ8149. Reivindicación 11: Una formulación inmunogénica de acuerdo a la cláusula 10, caracterizada porque los 8 diferentes tipos de proteína M corresponden a M1, M2, M4, M6, M9, M12, M22 y M28. Reivindicación 13: Un método para producir una vacuna de administración intranasal caracterizado porque comprende los pasos de: clonar por separado el fragmento de la proteína M de S. pyogenes de los 8 tipos elegidos; insertar cada fragmento en un plasmidio; insertar los plasmidios conteniendo el fragmento de la proteína M en Lactococcus lactis; cultivar cada cepa en medio de cultivo apropiado para L. lactis; inducir el cultivo de Lactococcus lactis para que exprese el fragmento de la proteína M; seleccionar las bacterias Lactococcus lactis que expresan el fragmento de la proteína M que corresponden a las cepas bacterianas vaccinales; centrifugar las cepas bacterianas; mezclar las cepas que contienen cada uno de los fragmento de la proteína M; y adicionar un diluyente biológicamente aceptable para administración intranasal.An immunogenic formulation for inducing the immune response in a subject, comprising a mixture of strains of genetically modified non-pathogenic bacteria that each express a hypervariable segment of the different Streptococcus pyogenes M protein and a biologically acceptable diluent. Use of the immunogenic formulation to prepare an intranasal administration vaccine and a method of producing said vaccine. Claim 3: An immunogenic formulation according to clause 1, characterized in that the non-pathogenic bacteria correspond to lactic acid bacteria. Claim 4: An immunogenic formulation according to clause 3, characterized in that the lactic acid bacteria used are of the Lactococcus Iactis species. Claim 6: An immunogenic formulation according to clause 1, characterized in that the hypervariable segments of the S. pyogenes M protein are expressed in a construct. Claim 9: An immunogenic formulation according to clause 8, characterized in that the plasmid used is pNZ8149. Claim 11: An immunogenic formulation according to clause 10, characterized in that the 8 different types of M protein correspond to M1, M2, M4, M6, M9, M12, M22 and M28. Claim 13: A method for producing an intranasal administration vaccine characterized in that it comprises the steps of: cloning separately the S. pyogenes M protein fragment of the 8 types chosen; insert each fragment into a plasmid; insert plasmids containing the M protein fragment into Lactococcus lactis; cultivate each strain in culture medium appropriate for L. lactis; induce the culture of Lactococcus lactis to express the M protein fragment; select the Lactococcus lactis bacteria that express the M protein fragment that correspond to the bacterial vaccinal strains; centrifuge bacterial strains; mix the strains that contain each of the M protein fragments; and add a biologically acceptable diluent for intranasal administration.

ARP140103580A 2013-09-27 2014-09-26 NASAL USE VACCINES AGAINST STREPTOCOCCUS PYOGENES BASED ON A WASTE BACTERIAL VECTOR AND SPECIFIC ANTIGENS, PRODUCTION METHOD AR097790A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2013002782A CL2013002782A1 (en) 2013-09-27 2013-09-27 Immunogenic formulation to induce the immune response in a subject comprising a mixture of non-pathogenic bacteria each expressing a hypervariable segment of the m protein of different streptococcus pyogenes; use of the formulation to produce a vaccine; method to produce vaccine

Publications (1)

Publication Number Publication Date
AR097790A1 true AR097790A1 (en) 2016-04-13

Family

ID=52742178

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103580A AR097790A1 (en) 2013-09-27 2014-09-26 NASAL USE VACCINES AGAINST STREPTOCOCCUS PYOGENES BASED ON A WASTE BACTERIAL VECTOR AND SPECIFIC ANTIGENS, PRODUCTION METHOD

Country Status (3)

Country Link
AR (1) AR097790A1 (en)
CL (1) CL2013002782A1 (en)
WO (1) WO2015044909A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112760336A (en) * 2020-12-30 2021-05-07 广州辉园苑医药科技有限公司 Expression system and surface display system of epitope peptide and construction method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5128593A (en) * 1992-09-16 1994-04-12 University Of Tennessee Research Corporation, The Antigen of hybrid m protein and carrier for group a streptococcal vaccine
EP1003875B1 (en) * 1997-09-12 2006-12-27 University of Tennessee Research Foundation Group a streptococcal vaccines
AU2002365184A1 (en) * 2001-10-26 2003-07-30 Id Biomedical Corporation Of Washington Efficient protein expression system
US20090010929A1 (en) * 2006-12-04 2009-01-08 Good Michael F Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates

Also Published As

Publication number Publication date
WO2015044909A1 (en) 2015-04-02
CL2013002782A1 (en) 2014-04-25

Similar Documents

Publication Publication Date Title
WO2013006055A8 (en) A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
MX2018002705A (en) Yeast strains for the expression and secretion of heterologous proteins at high temperatures.
MX363529B (en) Outer membrane vesicles.
McCaig et al. Characterization and vaccine potential of outer membrane vesicles produced by Haemophilus parasuis
MX2013010620A (en) Non-pathogenic serotype 4 fowl adenovirus (fadv-4) and viral vector thereof.
PH12017501445A1 (en) Methods for producing virus for vaccine production
BR112013009583A2 (en) nucleic acid, vector, host cell, methods of preparing a bacterial lineage variant for typing, marking, generating and controlling bacterial populations, variant bacterial cell line and variant, kit, use of a nucleic acid, cell culture, product, product preparation process, phage mutants and phage escape mutant
UA112435C2 (en) COMPOSITION SUITABLE FOR MILK PRODUCTS CONTAINING LACTOBACILLUS RHAMNOSUS
MX352974B (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof.
MX2016016885A (en) In ovo delivery of probiotic cultures.
MX2011012234A (en) Antibiotic-free plasmid.
AR107069A1 (en) BACTERIA OF THE LACTIC ACID TO PREPARE FERMENTED EDIBLE PRODUCTS WITH GREATER NATURE AND HIGH TEXTURE
BR112015000585A8 (en) method for preparing a mutant strain of mycoplasma hyopneumoniae, vectors, mutant strain, vaccine, vaccination kit, and uses of the vector and mutant strain
EA201890407A1 (en) BACTERIA LACTOBACILLUS FERMENTUM REDUCING THE CONCENTRATION OF ACETALDEHYDE
MX2017000014A (en) METHOD FOR PRODUCING MEDIUM-CHAIN FATTY ACID USING ß-KETOACYL-ACP SYNTHASE.
MY191217A (en) Group a streptococcus vaccine
MY169049A (en) Microorganisms for producing putrescine and process for producing putrescine using them
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
MX2020007300A (en) Fermented milk product and preparation thereof using phospholipase.
MX2014001626A (en) Vacuum -assisted preservation of biological products, in particular of vaccines.
BR112014020025A8 (en) ROTAVIRUS SUBUNIT VACCINES AND PRODUCTION METHODS AND USE THEREOF
AR097790A1 (en) NASAL USE VACCINES AGAINST STREPTOCOCCUS PYOGENES BASED ON A WASTE BACTERIAL VECTOR AND SPECIFIC ANTIGENS, PRODUCTION METHOD
WO2013019603A3 (en) Linear expression cassettes and uses thereof
Suebwongsa et al. Development of an Escherichia coli–Lactobacillus casei shuttle vector for heterologous protein expression in Lactobacillus casei
CO2018007607A2 (en) Compositions and methods of use of novel strains of lactobacillus fermentum

Legal Events

Date Code Title Description
FB Suspension of granting procedure